Amerinet Awards Positron Group Purchasing Agreement

FISHERS, Ind., Dec. 2, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, is pleased to announce that Amerinet has awarded a Group Purchasing Agreement for their PosiRx system to begin January 1, 2012 for a three-year period. 

Amerinet is a Group Purchasing Organization (GPO), which enters into arrangements for the purchase of products and services on behalf of its member facilities. Amerinet provides a broad portfolio of agreements, products and services capable of serving healthcare organizations, both hospitals and non-hospitals alike. Amerinet's objective is to secure new opportunities with emerging technology vendors in order to reduce costs and improve efficiencies to its member network.

Positron's objective is to offer the PosiRx System throughout Amerinet's network of over 50,000 members.  Positron's PosiRx technology will meet the needs of those Amerinet members desiring efficient radiopharmaceutical solutions for their cardiac SPECT pharmacy needs.

"We believe the PosiRx system will impact and redefine the industry by offering a more efficient and economical alternative to the current nuclear pharmacy model.  We are excited to work with Amerinet and their extensive member network, as our innovative solutions are well-aligned with their vision," stated Michael Stewart, Positron's Director of Radiopharmaceutical Business Development.

PosiRx is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging.  It was created to simplify and control the procedures associated with compounding radiopharmaceuticals.  PosiRx is the first system of its kind to offer a complete and comprehensive automated solution in nuclear medicine.

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

About Amerinet:  As a leading national healthcare solutions organization, Amerinet collaborates with acute and non-acute care providers to create and deliver unique solutions through performance improvement resources, guidance and ongoing support. With better product standardization and utilization, new financial tools beyond contracting and alliances that help lower costs, raise revenue and champion quality, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about how Amerinet can help you successfully navigate the future of healthcare reform, visit www.amerinet-gpo.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation